Show simple item record

dc.contributor.authorKoeken, Valerie A C M
dc.contributor.authorGaniem, Ahmad R
dc.contributor.authorDian, Sofiati
dc.contributor.authorRuslami, Rovina
dc.contributor.authorChaidir, Lidya
dc.contributor.authorNetea, Mihai G
dc.contributor.authorKumar, Vinod
dc.contributor.authorAlisjahbana, Bachti
dc.contributor.authorvan Crevel, Reinout
dc.contributor.authorvan Laarhoven, Arjan
dc.date.accessioned2020-12-09T09:45:09Z
dc.date.available2020-12-09T09:45:09Z
dc.date.issued2020-07-30
dc.identifier.citationJ Hepatol. 2020 Jul 30:S0168-8278(20)30492-X. doi: 10.1016/j.jhep.2020.07.039. Epub ahead of print.en_US
dc.identifier.pmid33202351
dc.identifier.doi10.1016/j.tube.2020.102019
dc.identifier.urihttp://hdl.handle.net/10033/622638
dc.description.abstractBackground & aims: Hepatocellular carcinoma (HCC) is a cancer with multiple aetiologies and widespread prevalence. Largely refractory to current treatments, HCC is the fourth leading cause of cancer-related deaths worldwide. MicroRNAs (miRNAs) are important regulators in HCCs. We aimed to identify tumour suppressor miRNAs during tumour regression in a conditional c-MYC-driven mouse model (LT2/MYC) of HCC, and to evaluate their therapeutic potential for HCC treatment. Methods: We performed miRNA expression profiling of developed and regressing LT2/MYC tumours and in-depth in vitro gain- and loss-of-function analyses. The effect of adeno-associated virus (AAV) vector-mediated miR-342-3p treatment was evaluated in 3 HCC mouse models. Results: We identified miR-342-3p as a tumour suppressor miRNA in HCC, with increased expression in regressing tumours. Forced miR-342-3p expression in hepatoma cells showed significantly decreased cell proliferation, migration, and colony formation. In vivo administration of AAV-miR-342-3p led to significant attenuation of tumour development and increased overall survival. We identified monocarboxylic acid transporter 1 (MCT1) as a bona fide target of miR-342-3p in HCC. We show that the tumour suppressor role of miR-342-3p is executed partly by modulating the lactate transport function of MCT1. Importantly, we find miR-342-3p downregulated in tumours from patients with HCC compared with matched non-tumour tissues, inversely correlating with MCT1 expression. We observed similar findings in TCGA-LIHC data. Conclusions: In our study, we identified and validated miR-342-3p as a tumour suppressor miRNA in HCC. We demonstrated its therapeutic efficacy in significantly attenuating tumour development, and prolonging survival, in different HCC mouse models. Identification of miR-342-3p as an effective tumour suppressor opens a therapeutic avenue for miRNA-mediated attenuation of HCC development. Lay summary: Hepatocellular carcinoma (HCC), the most common type of liver cancer, affects diverse populations and has a global impact, being the fourth leading cause of cancer deaths worldwide. There are currently no systemic therapies for HCC that can significantly prolong long-term survival. Thus, novel effective treatment options are urgently required. To understand the molecular basis of tumour regression, we compared tumours and regressing liver tumours in mice. We show that a small non-coding miRNA, miR-342-3p, is a tumour suppressor in HCC. Expression of miR-342-3p is low in tumours and high in regressing tumours. When miR-342-3p is delivered to mouse livers with HCC, it can significantly slow down liver tumour development and improve survival. Our study highlights the promising therapeutic potential of miR-342-3p intervention in HCC.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectInterleukin-1βen_US
dc.subjectMortalityen_US
dc.subjectTuberculous meningitisen_US
dc.titleCerebrospinal fluid IL-1β is elevated in tuberculous meningitis patients but not associated with mortality.en_US
dc.typeArticleen_US
dc.identifier.eissn1873-281X
dc.contributor.departmentCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.en_US
dc.identifier.journalTuberculosis (Edinburgh, Scotland)en_US
dc.source.volume126
dc.source.beginpage102019
dc.source.endpage
refterms.dateFOA2020-12-09T09:45:09Z
dc.source.journaltitleTuberculosis (Edinburgh, Scotland)
dc.source.countryUnited Kingdom
dc.source.countryScotland


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Koeken et al.pdf
Size:
953.0Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International